- SOUL trial assessed oral semaglutide in type 2 diabetes patients with cardiovascular/kidney disease.
- Lower incidence of major adverse cardiovascular events with oral semaglutide.
- Mean HbA1c reduction and weight loss observed with semaglutide.
- Gastrointestinal side effects and treatment discontinuation more frequent with semaglutide.
- Benefits consistent across prespecified subgroups.
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
